LUND, SWEDEN / ACCESSWIRE / January 8, 2025 / BioInvent International (STO:BINV)BI-1910 single agent Phase 1 Part A dose escalation has been completed and reached a biologically active dose level. Dat ...

A retrospective chart review compared the difference in outcomes between Black patients and White patients with advanced RCC for 3 first-line therapies.

The SU2C-SARC032 study demonstrated that pembrolizumab combined with radiotherapy and surgery was well tolerated, with ...

NDAQ:NAYA) NAYA Biosciences Announces Development of NY-500, a Novel AI-Optimized PD-1 x VEGF Bifunctional Antibody ...

Multi-centre trial evaluating efti in combination with pembrolizumab and chemotherapy in patients with non-small cell lung ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

FYB-206 is under development for the treatment of malignant melanoma (black skin cancer) and non-small cell lung cancer. The drug candidate is a pembrolizumab biosimilar. It acts by targeting ...

James “Jimmy” Carter, the 39th President of the United States, passed away last week on December 29, after 22 months in Hospice care.  At | Cancer ...

Potential practice-changing therapies in gynecologic cancer include the emergence of carboplatin, paclitaxel, and PD-1 ...

That small trial and its remarkable results epitomize the ideal of modern cancer research: patients were enrolled based on a ...

The past 12 months have seen the FDA approvals of enfortumab vedotin plus pembrolizumab for patients with locally advanced or ...